Breaking News, Collaborations & Alliances

Roche, Shape Therapeutics Enter Strategic Gene Therapy Collaboration

ShapeTX will apply its RNA editing platform and leverage its AAVid technology platform for the development of gene therapy for various diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Shape Therapeutics Inc., a biotechnology company developing RNA technologies to shape the future of gene therapy, has announced a multi-target strategic collaboration and license agreement with Roche.   Through this partnership, ShapeTX will apply its proprietary RNA editing platform RNAfix and potentially leverage its AAVid technology platform for next-generation tissue-specific adeno-associated viruses (AAVs) for the development of gene therapy for certain targets in the areas of Alzheimer’s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters